Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Allogeneic HSC and regulatory T cell  (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

View Full Paper
Ask AI
Bookmark
Share

Authors

LJLaura JohnstonARAndrew R. RezvaniEMEverett Meyer

Discussion

Loading...

Member takes

Overview

Phase 1 trial shows Orca-T reduces graft versus host disease in hematological malignancies, indicating feasibility in RIC-HSCT.

Key Points

  • To assess the feasibility and safety of Orca-T cell therapy with reduced intensity conditioning in transplant patients.
  • Single-center, open-label, Phase 1 trial design
  • Enrolled 49 patients with hematological malignancies
  • Evaluated endpoints include incidence of acGvHD, RFS, and OS
  • Median follow-up of 13.2 months with no manufacturing failures
  • 1-year cumulative incidence of aGvHD at 14%, mostly grade II
  • 1-year OS estimated at 85% with low rates of NRM

Cite This Study

Johnston et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfechttps://doi.org/10.1182/blood-2025-111
View Full Paper
Ask AI
Bookmark
Share